Belrestotug

Summary

Belrestotug (CHEMBL4802205) is a phase-3 clinical-stage antibody; indicated across 5 conditions including non-small cell lung carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802205
Name	Belrestotug
Type	Antibody
Max phase	3

Also known as: Belrestotug, Clone 31282, EOS-448, Eos-884448, EOS-884448, Eos884448, EOS884448, GSK-4428859A, GSK4428859A, WB-2127, WB2127, WBP2127

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
neoplasm	2	MONDO:0005070	EFO:0000616
head and neck neoplasm	2	MONDO:0005586	EFO:0005950
plasma cell myeloma	1	MONDO:0009693	EFO:0001378

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06472076	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT05060432	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
NCT05565378	PHASE2	ACTIVE_NOT_RECRUITING	A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT06062420	PHASE2	ACTIVE_NOT_RECRUITING	A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT03739710	PHASE2	COMPLETED	Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
NCT04446351	PHASE1	ACTIVE_NOT_RECRUITING	Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
NCT05277051	PHASE1	ACTIVE_NOT_RECRUITING	First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT04335253	PHASE1	COMPLETED	First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
NCT05289492	PHASE1	TERMINATED	Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).